Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026

Kezar Life Sciences Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
54464969481822
Market Cap Growth
55.19%-6.05%-28.81%-85.69%-41.42%240.23%
Enterprise Value
-11-34-82-130204706
Last Close Price
7.296.296.729.4770.40167.20

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---9.84--
PB Ratio
0.820.660.420.371.784.17
P/TBV Ratio
0.830.660.420.371.784.17

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.020.030.140.100.080.07
Net Debt / Equity Ratio
-0.99-0.99-0.99-0.97-0.95-0.99
Net Debt / EBITDA Ratio
1.591.351.321.753.643.66
Net Debt / FCF Ratio
1.541.341.562.194.224.55
Asset Turnover
---0.03--
Quick Ratio
23.9811.236.5311.4825.2225.37
Current Ratio
24.4611.526.7611.6625.9825.77
Return on Equity (ROE)
-53.75%-59.93%-55.00%-44.54%-29.24%-32.34%
Return on Assets (ROA)
-26.77%-29.52%-30.45%-25.26%-17.19%-18.48%
Return on Capital Employed (ROCE)
-63.50%-74.60%-71.70%-51.70%-24.70%-26.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-83.99%-121.65%-170.78%-147.92%-14.18%-6.65%
FCF Yield
-78.04%-112.42%-151.42%-121.18%-12.55%-5.20%
Buyback Yield / Dilution
-0.41%-0.36%-0.48%-7.70%-27.69%-19.90%
SEC Filings: 10-K · 10-Q